A5050495630- Lymphoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Viral-associated cancers and disorders
- Lung Cancer Research Studies
- Chronic Lymphocytic Leukemia Research
- Lung Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- RNA modifications and cancer
- Gastric Cancer Management and Outcomes
- CNS Lymphoma Diagnosis and Treatment
- Brain Metastases and Treatment
- Neutropenia and Cancer Infections
- Hematopoietic Stem Cell Transplantation
- Cancer Treatment and Pharmacology
- T-cell and Retrovirus Studies
- Inflammatory Biomarkers in Disease Prognosis
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- Sarcoma Diagnosis and Treatment
- Cancer therapeutics and mechanisms
- Radiomics and Machine Learning in Medical Imaging
- Salivary Gland Tumors Diagnosis and Treatment
Chinese Academy of Medical Sciences & Peking Union Medical College
2016-2025
Jianghan University
2025
National Clinical Research
2019-2024
Ten Chen Hospital
2024
Tongji University
2022-2023
Shanghai Tenth People's Hospital
2022-2023
Capital University
2023
Capital Medical University
2023
Beijing Anzhen Hospital
2023
Peking Union Medical College Hospital
2019-2022
HLA-Cw6 is strongly associated with psoriasis and has been suggested to be the PSORS1 gene that confers susceptibility early-onset psoriasis. In this study of clinical features HLA-Cw*0602-positive -negative patients in a Han Chinese population, we typed HLA-C cohort 679 compared two groups. Cw*0602-positive (n=345) had an earlier disease onset (p < 1 x 10(-5)), more severe 10(-3)), higher frequency guttate 10(-9)), affected legs trunk incidence Köbner's phenomenon (p=0.005) trauma history...
Background: Programmed cell death protein 1 (PD1) inhibitors have revolutionized cancer therapy, yet many patients fail to respond.Thus, the identification of accurate predictive biomarkers therapy response will improve clinical benefit anti-PD1 therapy.Method: We assessed baseline serological autoantibody (AAb) profile against ~2300 proteins in 10 samples and ~4600 35 with alveolar soft part sarcoma (ASPS), non-small-cell lung (NSCLC) lymphoma using Nucleic Acid Programmable Protein Arrays...
Alzheimer's disease (AD) pathogenesis involves progressive synaptic degeneration, a process potentially driven by maladaptive microglial pruning activity. While loss is hallmark of AD, the molecular signals triggering pathological microglia-mediated engulfment remain elusive. Clec7a-a key marker disease-associated microglia (DAM)-is known to activate spleen tyrosine kinase (SYK) signaling, enhancing Aβ phagocytosis and neuroprotective functions in 5×FAD models. However, its role regulating...
Abstract Aim Apatinib, an oral tyrosine kinase inhibitor mainly targeting VEGFR‐2, exerts both antiangiogenesis and antiproliferation effects. Apatinib shows clinical benefit in advanced non‐small cell lung cancer (NSCLC) at initial dose of 750 mg qd. We further assessed the efficacy safety apatinib a more frequently used 500 The preliminary outcome patients with brain metastases was also reported. Methods retrospectively reviewed data 25 who received between August 2015 May 2016....
Primary breast diffuse large B‐cell lymphoma ( PB ‐ DLBCL ) is a rare subtype of with limited data on patterns failure. This multicenter study aimed to define the optimum treatment strategy and failure for patients. We retrospectively reviewed 108 patients from 21 Chinese medical centers. Only localized disease (involvement lymph nodes) were included. After median follow‐up 3.2 years, 32% developed progression or relapse. A continuous pattern relapse was observed, characterized by frequent...
Chemotherapy is the preferred treatment in many types of cancer including lung cancer. However, most patients resist chemotherapy resulting disease progressive and recurrence. Titin (TTN) mutation proved as a beneficial role squamous carcinoma (LUSC), but predictive on resistance still limited discussable.Clinical information related somatic profiles were obtained from The Cancer Genome Atlas (TCGA) database analyzed by R-Studio using R-package. Overall survival (OS) curve association...
Background: Gastric cancer (GC) is one of the major malignancies threatening human lives and health. Non-SMC condensin II complex subunit D3 ( NCAPD3 ) plays a crucial role in occurrence many diseases. However, its GC remains unexplored. Materials Methods: The Cancer Genome Atlas (TCGA) database, clinical samples, cell lines were used to analyze expression GC. was overexpressed inhibited by lentiviral vectors CRISPR/Cas9 system, respectively. biological functions investigated vitro vivo ....
Background: Lung adenocarcinoma (LUAD) possesses a poor prognosis with low 5-year survival rate even for stages I-III resected patients, it is thus critical to understand the determinants that affect and discover new potentially prognostic biomarkers. Somatic copy number alterations (CNAs) are major source of genomic variations driving tumor evolution, CNAs screening may identify Methods: Oncoscan MIP array was used analyze patterns on formalin fixed paraffin embedded(FFPE) specimens from...
Objectives The study aimed to conduct a bibliometric analysis of publications concerning lumbar spondylolisthesis, as well summarize its research topics and hotspot trends with machine-learning based text mining. Methods data were extracted from the Web Science Core Collection (WoSCC) database then analyzed in Rstudio1.3.1 CiteSpace5.8. Annual publication production top-20 productive authors over time obtained. Additionally, journals influential compared by spine-subspecialty or not....
Rezivertinib (BPI-7711) is a novel third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). This phase IIa study was part of I/IIa (NCT03386955), aimed to evaluate the efficacy and safety rezivertinib as first-line treatment for patients with locally advanced or metastatic/recurrent EGFR mutated non-small cell lung cancer (NSCLC).
Limited data are available to guide the choice of conditioning regimen before autologous hematopoietic stem cell transplantation (AHSCT) for patients with lymphoma.We analyzed 129 non-Hodgkin lymphoma who underwent AHSCT from 1996 2013 using most common regimens: CBV (cyclophosphamide, carmustine and etoposide; n = 16), BEAM (carmustine, etoposide, cytarabine melphalan; 36) BEAC cyclophosphamide; 77).At a median follow-up 42.5 months, estimated 5-year overall survival CBV, groups was 68.8%,...
BPI-9016M is a novel small-molecule inhibitor that simultaneously targets both c-Met and AXL tyrosine kinases. This phase I study aimed to determine the maximum tolerated dose (MTD), safety, pharmacokinetics, antitumor activity of in Chinese patients with advanced non-small cell lung cancer (NSCLC).Over range 100 mg 800 mg, eligible were administered single 9016M tablet received 7 days pharmacokinetics evaluation, followed by continuous administration (QD dosing, 28 days). Standard "3 + 3"...
Abstract The response rate of anti-PD1 therapy is limited, and the influence on cancer patients unclear. To address these challenges, we conducted a longitudinal analysis plasma proteomic changes with in non-small cell lung (NSCLC), alveolar soft part sarcoma (ASPS), lymphoma patients. We included 339 samples before after from 193 NSCLC, ASPS, or lymphoma. proteins were detected using data-independent acquisition-mass spectrometry customable antibody microarrays. Differential characteristics...
Abstract Background: Factors affecting progenitor cell mobilization in patients with non‐Hodgkin's lymphoma (NHL) and Hodgkin's (HL) are incompletely understood. The aim of this retrospective study was to determine which factors crucial for effective collection autologous peripheral blood stem cells (PBSC) prior transplantation Chinese patients. Patients methods: A total 239 (198 NHL 41 HL patients) underwent PBSC after granulocyte‐colony‐stimulating factor (G‐CSF) or G‐CSF plus chemotherapy...